RVNC News and Press, Revance Therapeutics Inc. From 04/07/20

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the company will participate in the 19th Annual Ne...

Key Changes to 2020 Plan : - Launch of RHA® fillers, and associated hiring of 100 field representatives, pushed back one quarter due to COVID-19 situation and temporary closure of Teoxane’s Swiss manufacturing facility - - JUNIPER Phase 2 trial for adult upper limb spas...

AbbVie (NYSE: ABBV ) downgraded to Hold at Societe Generale. More news on: AbbVie Inc., Tandem Diabetes Care, Inc., Universal Health Services, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Revance Therapeutics, Inc. (NASDAQ: RVNC) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Revance reported earnings yesterday. 4Q19 EPS of $(0.99) was slightly below FactSet consensus of $(0.95) which we believe it is immaterial...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the company will participate in the Cowen 40th Ann...

Image source: The Motley Fool. Revance Therapeutics   (NASDAQ: RVNC) Q4 2019 Earnings Call Feb 24, 2020 , 4:30 p.m. ET Operator Continue reading

Revance Therapeutics, Inc. (RVNC) Q4 2019 Results Earnings Conference Call February 24, 2020, 4:30 am ET Company Participants Jeanie Herbert - Senior Director of Investor Relations and Corporate Communications Mark Foley - President, Chief Executive Officer Dustin Sjuts - Chief C...

Revance Therapeutics (NASDAQ: RVNC ): Q4 GAAP EPS of -$0.99 misses by $0.05 . More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Conference call and webcast today at 4:30 p.m. ET - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today repo...

Conference Call Scheduled for Monday, February 24, 2020 at 4:30 p.m. ET Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection ...